Glyscend Therapeutics

Glyscend Therapeutics

Biotechnology, 1812 Ashland Ave 110, Lowell, Massachusetts, 21205, United States, 11-50 Employees

glyscend.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 14*********

Who is GLYSCEND THERAPEUTICS

Developer of oral, gut-targeted polymer therapeutics for the treatment of metabolic indications such as type 2 diabetes, and other chronic conditions. The company is developing a lead dru...

Read More

map
  • 1812 Ashland Ave 110, Lowell, Massachusetts, 21205, United States Headquarters: 1812 Ashland Ave 110, Lowell, Massachusetts, 21205, United States
  • 2014 Date Founded: 2014
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8731

checked-icon Does something look wrong? Fix it. | View contact records from GLYSCEND THERAPEUTICS

Glyscend Therapeutics Org Chart and Mapping

Employees

Christine Bryant

Sr. Director of Clinical and Translational Science

Kevin Colbert

Senior Director of Operations & Strategy

Ashish Nimgaonkar

Founder, Chief Medical Officer and Head of R&D

Mark Fineman

Chief Development Officer

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Glyscend Therapeutics

Answer: Glyscend Therapeutics's headquarters are located at 1812 Ashland Ave 110, Lowell, Massachusetts, 21205, United States

Answer: Glyscend Therapeutics's phone number is 14*********

Answer: Glyscend Therapeutics's official website is https://glyscend.com

Answer: Glyscend Therapeutics's revenue is $1 Million to $5 Million

Answer: Glyscend Therapeutics's SIC: 8731

Answer: Glyscend Therapeutics has 11-50 employees

Answer: Glyscend Therapeutics is in Biotechnology

Answer: Glyscend Therapeutics contact info: Phone number: 14********* Website: https://glyscend.com

Answer: Developer of oral, gut-targeted polymer therapeutics for the treatment of metabolic indications such as type 2 diabetes, and other chronic conditions. The company is developing a lead drug, which is orally administered, non-absorbed, gut-restricted duodenal exclusion therapy designed to replicate the metabolic effects of bariatric surgery with safety-advantages avoiding invasive complications of surgeries and procedures.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access